Zim Laboratories Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Published 24 May 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹614 Cr

Steady growth expected in Oral Thin Films (OTF), with significant revenue anticipated in FY27 due to new partnerships and increased local manufacturing focus. FY27 growth is expected despite ongoing geopolitical and regulatory challenges, with revenue growth projected from NIP and OTF products, especially from rest of world (RoW) and pharmerging markets (Pages 28, 29).

From Zim Laboratories Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹125

Market Cap

₹614 Cr

P/E Ratio

141.2

How does Zim Laboratories Ltd rank in Pharmaceuticals & Biotechnology?

Compare Zim Laboratories Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Zim Laboratories Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹105 Cr, net profit ₹4 Cr.

Full financials →

📊 Revenue & Sales Performance

→Steady growth expected in Oral Thin Films (OTF), with significant revenue anticipated in FY27 due to new partnerships and increased local manufacturing focus.
→NIP (Novel Innovative Products) and OTF businesses projected to grow in FY27 despite EU GMP delays, driven by dossier approvals in RoW and pharmerging markets.
→Target to have 50% of business from NIP and OTF innovative products, with ~30% from regulated markets and ~20% from RoW/pharmerging markets in coming years.
→Anticipated 10-15% annual overall revenue growth, with margins improving to mid to upper teens percentage post-CAPA remediation and EU GMP approval.
→Full commercialization of 17 NIP plus OTF products expected within 24 months, supporting sustained revenue ramp-up.
→Expected EBITDA margins in upper teens (~20% range) as ramp-up and regulatory approvals progress.
→Continued investment in R&D balanced with operational readiness for disciplined execution and scale-up.

📈 Profitability & Margins

→FY27 growth is expected despite ongoing geopolitical and regulatory challenges, with revenue growth projected from NIP and OTF products, especially from rest of world (RoW) and pharmerging markets (Pages 28, 29).
→EU GMP approval anticipated within 2-3 months (around Q3 FY27), enabling commercial shipments from Q4 FY27 and supporting regulated market revenue growth (Pages 14, 30).
→NIP plus OTF revenues targeted to grow significantly, aiming to reach about 50% of total business over the medium term; commercialization of 17 products expected within 24 months (Pages 17, 22, 29).
→EBITDA margins projected to improve to mid to upper teens percentage post EU GMP certification and scale-up (Page 28, 13).
→Stable sustainable NIP run rate around INR 16-18 crore expected, with potential upside as new markets open (Page 20).
→Continued investment in R&D with selective increase in product pipeline supports future earnings growth (Page 14).
→Overall conservative revenue growth of 10-15% per year targeted, margin expansion expected post remediation and scale-up (Page 15, 28).

See what Zim Laboratories Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→Majority of CapEx related to 17 innovative products (NIP and OTF) is near completion; only last stages left, no significant further investment anticipated.
→Recent preferential allotment of INR 35 crore raised for three main projects: dedicated enzyme NIP suite, nutraceutical plant expansion, and CAPA remediation.
→Enzyme product CapEx largely completed, currently only maintenance CapEx planned.
→New block/facility created to cater to increased capacity for certain products, though existing plants can also manufacture.
→No plans to increase borrowings further; prefer issue money to be used for CapEx.
→Strategic investments include alternate certification and site transfer activities to ensure business continuity.
→Company is digitally upgrading for quality and data integrity improvements, investing in systems like German environmental monitoring and e-logbooks as part of CAPA.

💰 Fundraising & Capital Structure

→No plans to increase borrowings any further this year; borrowing and finance cost expected to remain constant. (Page 21)
→Preferential allotment of INR 35 crore to Florintree Trinix LLP has already been utilized/planned for three main projects including enzyme NIP suite, nutraceutical plant expansion, and CAPA. (Page 16)
→No explicit mention of fresh equity fundraising apart from recent preferential allotment; future fundraising details not indicated in the transcript.
→Overall, the company is managing existing debt and capex through internal resources and prior fundraises without new debt or equity planned in the immediate term. (Pages 16, 21)

See what Zim Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

→The transcript does not explicitly provide specific figures or details about the current or expected order book or pending orders for Zim Laboratories Limited as of Q4 FY26.
→However, it is noted that the company is awaiting EU GMP certification, expected within 2-3 months from the call date (May 2026), which will enable commercial orders, especially for new innovative products (NIP) and Oral Thin Films (OTF).
→Commercialization of 17 products within the next 24 months is projected, conditional on regulatory approvals and EU GMP certification.
→The company expects significant revenue growth from OTF this year due to strategic partnerships, particularly in the Middle East.
→Post EU GMP certification, NIP products are expected to start generating revenue in Q4 FY27.
→There is a focus on recovering and expanding business in regulated markets and ROW markets via these approvals.
→No concrete order book numbers were shared during the call.

Key Metrics

What Zim Laboratories's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
Sai Parenterals Ltd (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Zim Laboratories Ltd Q4 FY26 results?

What is Zim Laboratories Ltd share price analysis?

Zim Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 141.2 with a market cap of ₹614 Cr. Investors should review the full earnings analysis for detailed insights.

Is Zim Laboratories Ltd planning capital expenditure?

Majority of CapEx related to 17 innovative products (NIP and OTF) is near completion; only last stages left, no significant further investment anticipated.

Keep Zim Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.